Why do some patients with depression not respond adequately to their first trial of antidepressants, or stop taking their medication within the first three months?
Why do some patients with depression not respond adequately to their first trial of antidepressants, or stop taking their medication within the first three months?
Combining pharmacology and genetics, pharmacogenomics offers both an explanation and a potential solution for these common problems. In an interview with RACGP President Dr Harry Nespolon, Royal Adelaide Hospital Clinical Pharmacology Registrar Dr Tom Polasek discusses the use of these new tests to improve patient outcomes in mental health.
Listen here:
